Patients with moderate-severe atopic dermatitis are at high risk of having inadequate disease control, according to a cross-sectional study in JAMA Dermatology.
Study finds the combination of duplilumab and topical corticosteroids works in hard-to-treat atopic dermatitis cases in adult patients.
FDA approves early, pre-approval trials for pediatric cases
The skin care industry promotes products designed for sensitive skin, yet dermatologists are concerned about the use of skin care products for skin disease.
Skin biopsies from infants with atopic dermatitis feature important differences compared to adults with atopic dermatitis. These differences could change atopic dermatitis treatment for infants and toddlers with the disease, a study shows.
This week during the annual meeting of the American Academy of Dermatology in San Diego, Robert Sidbury, M.D., addressed developments in atopic dermatitis treatments since the publication of treatment guidelines in 2014.
All children, but healthy controls, had a higher likelihood of behavioral issues. ADHD symptoms of attention, hyperactivity and impulse control, were higher in AD children. Quality of life lower in affected children.
A daily capsule of a cocktail of probiotics may reduce both the severity symptoms in moderate atopic dermatitis and the need for topical corticosteroids to treat symptom flare ups in children.
In this article, Drs. Lawrence Eichenfield and Jessica Sprague review some of the most significant findings and developments in pediatric dermatology from the last year beginning with the availability of biologic agents for pediatric psoriasis and atopic dermatitis.
The first patient has been dosed in the phase two study of PR022 (hypochlorous acid, Realm Therapeutics), a topical gel treatment for patients with atopic dermatitis.